מחיר לרווח עתידי: Quest Diagnostics (DGX)

Quest Diagnostics demonstrates exceptional resilience to economic shocks due to insurance-backed demand. The company's forward P/E ratio helps determine market equilibrium, with the value stabilizing at 21.70. Aggressive acquisitions of hospital laboratories are currently offsetting a slowdown in organic growth. Service stability is supported only by slight seasonality during winter viral infection periods.

Quest Diagnostics is scaling its dominance in clinical diagnostics through acquisitions and the integration of AI into genetics. The company's expected NTM P/E, equal to 21.70, reflects the ratio of current market capitalization to projected net income. This metric is sensitive to currency fluctuations and the dynamics of import-export flows. Multiple compression signals undervaluation, whereas its growth amid stagnant revenues creates impairment risks. The stability of this indicator confirms the asset's fundamental resilience.